Drug Profile

AB 102 - Safety Shot

Alternative Names: AB-102 - Safety Shot

Latest Information Update: 27 Feb 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Applied Biology
Developer Safety Shot
Class Skin disorder therapies; Small molecules
Mechanism of Action Alpha 1 adrenergic receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Alopecia

Most Recent Events

28 Aug 2022 No recent reports of development identified for phase-I development in Alopecia(Prevention) in USA (Topical)
20 Feb 2019 Applied Biology plans a phase I trial for Alopecia (Prevention) (Topical) in Q3 2019 (Applied Biology pipeline, February 2019)
28 Nov 2017 Adverse events and pharmacodynamics data from a preclinical trial in Alopecia (Prevention) released by Applied Biology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com